UY32494A - Nuevas 2,4-diaminopirimidinas, sales farmacéuticas de las mismas, composiciones conteniéndolas y aplicaciones - Google Patents
Nuevas 2,4-diaminopirimidinas, sales farmacéuticas de las mismas, composiciones conteniéndolas y aplicacionesInfo
- Publication number
- UY32494A UY32494A UY0001032494A UY32494A UY32494A UY 32494 A UY32494 A UY 32494A UY 0001032494 A UY0001032494 A UY 0001032494A UY 32494 A UY32494 A UY 32494A UY 32494 A UY32494 A UY 32494A
- Authority
- UY
- Uruguay
- Prior art keywords
- diaminopirimidines
- applications
- new
- same
- compositions containing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
La presente invención comprende compuestos de la fórmula general /(1) en donde B, R1 a R5, Rx, m y n se definen como en la reivindicación 1, que son apropiados para el tratamiento de enfermedades que se caracterizan por proliferación celular excesiva o anómala, así como su uso en tal tratamiento.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09155515 | 2009-03-18 | ||
EP10153211 | 2010-02-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY32494A true UY32494A (es) | 2010-10-29 |
Family
ID=42111169
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001032494A UY32494A (es) | 2009-03-18 | 2010-03-16 | Nuevas 2,4-diaminopirimidinas, sales farmacéuticas de las mismas, composiciones conteniéndolas y aplicaciones |
Country Status (17)
Country | Link |
---|---|
US (2) | US20110071158A1 (es) |
EP (1) | EP2408752B1 (es) |
JP (1) | JP5628281B2 (es) |
KR (1) | KR20110128927A (es) |
CN (1) | CN102421762A (es) |
AR (1) | AR076134A1 (es) |
AU (1) | AU2010224881A1 (es) |
BR (1) | BRPI1013618A2 (es) |
CA (1) | CA2755759A1 (es) |
CL (1) | CL2011002300A1 (es) |
EA (1) | EA201101330A1 (es) |
IL (1) | IL214746A0 (es) |
MX (1) | MX2011009780A (es) |
TW (1) | TW201043611A (es) |
UY (1) | UY32494A (es) |
WO (1) | WO2010106097A1 (es) |
ZA (1) | ZA201105986B (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007146981A2 (en) * | 2006-06-15 | 2007-12-21 | Boehringer Ingelheim International Gmbh | 2-anilino-4-(heterocyclic)amino-pyrimidines as inhibitors of protein kinase c-alpha |
CA2723961C (en) | 2008-05-21 | 2017-03-21 | Ariad Pharmaceuticals, Inc. | Phosphorous derivatives as kinase inhibitors |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
US8412326B2 (en) * | 2009-10-30 | 2013-04-02 | Cardiac Pacemakers, Inc. | Pacemaker with vagal surge monitoring and response |
CA2797947C (en) | 2010-06-04 | 2019-07-09 | Charles Baker-Glenn | Aminopyrimidine derivatives as lrrk2 modulators |
US20120244141A1 (en) | 2010-09-28 | 2012-09-27 | Boehringer Ingelheim International Gmbh | Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors |
HUE046617T2 (hu) | 2010-11-10 | 2020-03-30 | Genentech Inc | Pirazol-aminopirimidin-származékok mint LRRK2 modulátorok |
EP2675794B1 (en) | 2011-02-17 | 2019-02-13 | Cancer Therapeutics Crc Pty Limited | Selective fak inhibitors |
CA2827171C (en) | 2011-02-17 | 2019-04-09 | Cancer Therapeutics Crc Pty Limited | Fak inhibitors |
CN103501612B (zh) | 2011-05-04 | 2017-03-29 | 阿里亚德医药股份有限公司 | 抑制表皮生长因子受体导致的癌症中细胞增殖的化合物 |
WO2013169401A1 (en) | 2012-05-05 | 2013-11-14 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
CA2890935A1 (en) * | 2012-11-08 | 2014-05-15 | Bristol-Myers Squibb Company | Alkyl amide-substituted pyrimidine compounds useful in the modulation of il-12, il-23 and/or ifn.alpha. |
US9145387B2 (en) | 2013-02-08 | 2015-09-29 | Celgene Avilomics Research, Inc. | ERK inhibitors and uses thereof |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
US10005760B2 (en) | 2014-08-13 | 2018-06-26 | Celgene Car Llc | Forms and compositions of an ERK inhibitor |
CN106146468B (zh) * | 2015-04-17 | 2020-12-01 | 杭州雷索药业有限公司 | 吡啶酮类蛋白激酶抑制剂 |
CN106478700B (zh) * | 2015-08-26 | 2020-12-29 | 杭州雷索药业有限公司 | 硼基取代的苯胺类蛋白激酶抑制剂 |
KR101992621B1 (ko) | 2017-12-07 | 2019-09-27 | 주식회사 온코빅스 | 암세포 성장 억제 효과를 나타내는 신규한 피리미딘 유도체 및 그를 포함하는 약제학적 조성물 |
WO2021003417A1 (en) | 2019-07-03 | 2021-01-07 | Sumitomo Dainippon Pharma Oncology, Inc. | Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69933680T2 (de) * | 1998-08-29 | 2007-08-23 | Astrazeneca Ab | Pyrimidine verbindungen |
OA11674A (en) * | 1998-11-10 | 2005-01-12 | Janssen Pharmaceutica Nv | HIV Replication inhibiting pyrimidines. |
GB9828511D0 (en) * | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
RS94703A (en) * | 2001-05-29 | 2007-02-05 | Schering Aktiengesellschaft, | Cdk inhibiting pyrimidines, production thereof and their use as medicaments |
EP2090571B1 (de) * | 2001-10-17 | 2012-05-16 | Boehringer Ingelheim Pharma GmbH & Co. KG | Pyrimidinderivate, Arzneimittel enthaltend diese Verbindungen, deren Verwendung und Verfahren zu ihrer Herstellung |
CA2473510A1 (en) * | 2002-01-23 | 2003-07-31 | Bayer Pharmaceuticals Corporation | Pyrimidine derivatives as rho-kinase inhibitors |
EP1562935B1 (de) * | 2002-10-28 | 2006-09-06 | Bayer HealthCare AG | Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren |
DE602004032446D1 (de) * | 2003-08-07 | 2011-06-09 | Rigel Pharmaceuticals Inc | 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel |
CA2566531A1 (en) * | 2004-05-18 | 2005-12-15 | Rigel Pharmaceuticals, Inc. | Cycloalkyl substituted pyrimidinediamine compounds and their uses |
EP1598343A1 (de) * | 2004-05-19 | 2005-11-23 | Boehringer Ingelheim International GmbH | 2-Arylaminopyrimidine als PLK Inhibitoren |
US7521457B2 (en) * | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
US20070032514A1 (en) * | 2005-07-01 | 2007-02-08 | Zahn Stephan K | 2,4-diamino-pyrimidines as aurora inhibitors |
AU2006327871A1 (en) * | 2005-12-21 | 2007-06-28 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
PE20080068A1 (es) * | 2006-05-15 | 2008-03-17 | Boehringer Ingelheim Int | Compuestos derivados de pirimidina como inhibidores de la quinasa aurora |
TWI432427B (zh) * | 2006-10-23 | 2014-04-01 | Cephalon Inc | 作為ALK及c-MET抑制劑之2,4-二胺基嘧啶之融合雙環衍生物 |
-
2010
- 2010-03-15 US US12/723,782 patent/US20110071158A1/en not_active Abandoned
- 2010-03-16 UY UY0001032494A patent/UY32494A/es not_active Application Discontinuation
- 2010-03-17 CN CN2010800203078A patent/CN102421762A/zh active Pending
- 2010-03-17 KR KR1020117024196A patent/KR20110128927A/ko not_active Application Discontinuation
- 2010-03-17 WO PCT/EP2010/053451 patent/WO2010106097A1/en active Application Filing
- 2010-03-17 BR BRPI1013618A patent/BRPI1013618A2/pt not_active Application Discontinuation
- 2010-03-17 AR ARP100100853A patent/AR076134A1/es unknown
- 2010-03-17 EP EP10709212.4A patent/EP2408752B1/en active Active
- 2010-03-17 JP JP2012500237A patent/JP5628281B2/ja active Active
- 2010-03-17 MX MX2011009780A patent/MX2011009780A/es not_active Application Discontinuation
- 2010-03-17 CA CA2755759A patent/CA2755759A1/en not_active Abandoned
- 2010-03-17 EA EA201101330A patent/EA201101330A1/ru unknown
- 2010-03-17 AU AU2010224881A patent/AU2010224881A1/en not_active Abandoned
- 2010-03-17 TW TW099107870A patent/TW201043611A/zh unknown
-
2011
- 2011-08-16 ZA ZA2011/05986A patent/ZA201105986B/en unknown
- 2011-08-18 IL IL214746A patent/IL214746A0/en unknown
- 2011-09-15 CL CL2011002300A patent/CL2011002300A1/es unknown
-
2013
- 2013-10-23 US US14/060,859 patent/US20140051674A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MX2011009780A (es) | 2011-09-30 |
AR076134A1 (es) | 2011-05-18 |
CA2755759A1 (en) | 2010-09-23 |
JP2012520850A (ja) | 2012-09-10 |
US20140051674A1 (en) | 2014-02-20 |
EP2408752B1 (en) | 2015-08-12 |
KR20110128927A (ko) | 2011-11-30 |
WO2010106097A1 (en) | 2010-09-23 |
CN102421762A (zh) | 2012-04-18 |
ZA201105986B (en) | 2012-08-29 |
EP2408752A1 (en) | 2012-01-25 |
BRPI1013618A2 (pt) | 2016-04-19 |
JP5628281B2 (ja) | 2014-11-19 |
EA201101330A1 (ru) | 2012-04-30 |
IL214746A0 (en) | 2011-11-30 |
TW201043611A (en) | 2010-12-16 |
US20110071158A1 (en) | 2011-03-24 |
CL2011002300A1 (es) | 2012-01-20 |
AU2010224881A1 (en) | 2011-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY32494A (es) | Nuevas 2,4-diaminopirimidinas, sales farmacéuticas de las mismas, composiciones conteniéndolas y aplicaciones | |
UY32916A (es) | Nuevas pirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones | |
UY32259A (es) | Nuevos compuestos de hidroxiareno, preparados farmaceuticos que los contienen y aplicaciones | |
ECSP13012448A (es) | Nuevas aminopirazoloquinazolinas. | |
UY32240A (es) | Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones. | |
UY31198A1 (es) | Amidas de ácidos benzoicos triazinil sustituidos, composiciones farmacéticas conteniéndolos y aplicaciones. | |
UY33199A (es) | 5-alquinil-pirimidinas. | |
CO6470845A2 (es) | Derivados de pirimidina novedosos y su uso en el tratamiento del cancer y enfermedades adicionales | |
ECSP11011558A (es) | Nuevos compuestos químicos. | |
UY32611A (es) | Compuestos de 1-cianoetilheterociclilcarboxamida sustituidos 750 | |
UY29636A1 (es) | 2,4-diamino-pirimidinas como inhibidores de aurora | |
UY33547A (es) | COMPUESTOS QUÍMICOS Bcl-2 y Bcl-XL | |
CR20120264A (es) | Compuestos | |
CL2011001967A1 (es) | Compuestos derivados de carboxamida-azaheterociclica sustituida, inhibidores de p70s6k, proceso de preparacion de estos; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias y cancer; kit farmaceutico. | |
CO6771439A2 (es) | Inhibidores de benzodioxano de la producción de leucotrieno | |
BR112012029647A2 (pt) | novos derivados de pirimidinas | |
UY33817A (es) | ?nuevas oxindolpirimidinas bencílicas?. | |
UY32009A (es) | 5-alquinil-pirimidinas | |
ECSP11010816A (es) | Nuevos Compuestos | |
UY31138A1 (es) | Derivados de indolinonas sustituidas, composiciones conteniendolos y aplicaciones | |
UY32748A (es) | 2-carboxamida-cicloamino-ureas | |
CO6290768A2 (es) | Tiazolil-dihidro-indazoles | |
CO6460762A2 (es) | 5-alquinil-piridinas | |
UY32747A (es) | 2-carboxamida-cicloamino-ureas sustituidas | |
ECSP12012110A (es) | 5-alquinil-pirimidinas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20190123 |